Table 3.

Frequency of KIR genes in chronic HBV patients and controls subjects.

KIR GENES n (%)	cHBV	CONTROL	crude OR (95%CI)	crude P value
Inhibitors
KIR2DL1
−	30 (27.3)	50 (37.3)	Ref.
+	80 (72.7)	84 (62.7)	1.59 (0.92–2.74)	0.097
KIR2DL2
−	63 (57.3)	106 (79.1)	Ref.
+	47 (42.7)	28 (20.9)	2.82 (1.61–4.96)	< 0.001
KIR2DL3
−	35 (31.8)	72 (53.7)	Ref.
+	75 (68.2)	62 (46.3)	2.49 (1.47–4.21)	< 0.001
KIR2DL4
−	33 (30.0)	36 (26.9)	Ref.
+	77 (70.0)	98 (73.1)	0.86 (0.49–1.5)	0.589
KIR2DL5A
−	70 (63.6)	84 (62.7)	Ref.
+	40 (36.4)	50 (37.3)	0.96 (0.57–1.62)	0.878
KIR2DL5B
−	61 (55.5)	74 (55.2)	Ref.
+	49 (45.5)	60 (44.8)	0.99 (0.60–1.64)	0.971
KIR3DL1
−	36 (32.7)	26 (19.4)	Ref.
+	74 (67.3)	108(80.6)	0.49 (0.28–0.89)	0.018
KIR3DL2
−	33 (30.0)	20 (14.9)	Ref.
+	77 (70.0)	114(85.1)	0.41 (0.22–0.77)	0.005
KIR3DL3
−	29 (26.4)	34 (25.4)	Ref.
+	81 (73.6)	100(74.6)	0.95 (0.53–1.69)	0.86
Activators
KIR2DS1
−	88 (80.0)	88 (65.7)	Ref.
+	22 (20.0)	46 (34.3)	0.48 (0.27–0.86)	0.014
KIR2DS2
−	65 (59.1)	114(85.1)	Ref.
+	45 (40.9)	20 (14.9)	3.95 (2.15–7.25)	< 0.001
KIR2DS3
−	92 (83.6)	110(82.1)	Ref.
+	18 (16.4)	24 (17.9)	0.9 (0.46–1.75)	0.75
KIR2DS4
−	43 (39.1)	56 (41.8)	Ref.
+	67 (60.9)	78 (58.2)	1.12 (0.67–1.87)	0.669
KIR2DS5
−	66 (60.0)	84 (62.7)	Ref.
+	44 (40.0)	50 (37.7)	1.12 (0.67–1.88)	0.668
KIR3DS1
−	98 (89.1)	122(91.0)	Ref.
+	12 (10.9)	12 (9.0)	1.24 (0.54–2.89)	0.611
Pseudogene
KIR2P1
−	51 (46.4)	40 (29.9)	Ref.
+	59 (53.6)	94 (70.1)	0.49 (0.29–0.83)	0.008